The importance of patient preference in the decision to screen for prostate cancer

Journal of General Internal Medicine

Volumn 11, Issue 6, 1996, Pages 342-349

  Flood, Ann Barry ^a   Wennberg, John E ^a   Nease Jr , Robert F ^b   Fowler Jr , Floyd J ^c   Ding, Jiao ^a   Hynes, Lynda M ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

medical decision making; patient preference; prostate cancer; screening test

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT EDUCATION; PROSTATE CANCER; PROSTATECTOMY; VIDEOTAPE;

EID: 0029979785     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02600045     Document Type: Article

References (22)

1. Mettlin CG, Johns HA, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-7.
2. Catalona W, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151:1283-90.
3. Kramer B, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-49.
4. U.S. Preventative Services Task Force. Screening for prostate cancer: commentary on the recommendations on the Canadian Task Force on the Periodic Health Examination. Am J Med. 1994;10: 187-93.
5. Canadian Task Force on the Periodic Health Examination. Periodic health examination 1991 update 3. Secondary prevention of prostate cancer. Can Med Assoc J. 1991;145:413-28.
6. Canadian Cancer Society and Institute for Clinical Evaluative Sciences. The info on prostate cancer and the PSA: no two men are the same. Ontario: Canadian Cancer Society: July 1995.
7. Canadian Urological Association. PSA guidelines: CUA changes it's position. CUA Newsletter 1995.
8. Handley MR, Stuart ME. The use of prostate specific antigen for prostate cancer screening: a managed care perspective. J Urol. 1994;152:1689-92.
9. Schroder FA. Detection of prostate cancer: screening the whole population has not yet been shown to be worth while. BMJ. 1995;310:140-1.
10. Schmid H, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer: the use of serial prostate specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031-40.
11. Stamey T, Frieha FS, McNeal JE, et al. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933-8.
12. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Homberg L, Krusemo U. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-6.
13. Johansson JE. Watchful waiting for early stage prostate cancer. Urol. 1994;43:138-42.
14. Wasson JH, Cushman CC, Bruskewitz RC, Litteuberg B, Mulley AG, Wennberg JE, and the Prostate Disease PORT. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 1993;2:487-93.
15. Fowler FJ, Barry MJ, Lu-Yao GL, Roman A, Wasson JH, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: the national Medicare experience: 1988-1990. Urology. 1993;42:622-9.
16. Monda J, Barry M, Oesterling J. Prostate-specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol. 1994;151:1291-5.
17. Sershon P, Barry M, Oesterling J. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ confined prostate cancer. Eur Urol. 1994;25:281-7.
18. Kassirer J. Incorporating patients' preferences into medical decisions. N Engl J Med. 1994;330:1895-6.
19. Chodak G. Screening for prostate cancer: the debate continues. JAMA. 1994;272:813-4.
20. Wasson JH, Reda DJ, Bruskewitz RC, for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med. 1995;32:75-9.
21. Black W, Nease RF Jr, Tosteson ANA. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87(10):720-31.
22. Lerrman C, Rimer B. Effects of individualized breast cancer risk counseling; a randomized trial. J Natl Cancer Inst. 1995;87(4): 286-92.